Locke, Frederick L.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 6,030

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation

CAR-T cell therapy researchCancer Immunotherapy and Biomarkers

Cited by 3,675

Chimeric antigen receptor T-cell therapy—assessment and management of toxicities

Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 2,438

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 2,286

KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma

Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., et al. (2020) · New England Journal of Medicine

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 1,862

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M.-A., Kersten, M.-J., Oluwole, O. O., Ghobadi, A., Rapoport, A. P., McGuirk, J., Pagel, J. M., et al. (2022) · New England Journal of Medicine

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 1,607

Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium

Nastoupil, L. J., Jain, M. D., Feng, L., Spiegel, J. Y., Ghobadi, A., Lin, Y., Dahiya, S., Lunning, M., Lekakis, L., Reagan, P., et al. (2020) · Journal of Clinical Oncology

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 801

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 570

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Locke, F. L., Rossi, J. M., Neelapu, S. S., Jacobson, C. A., Miklos, D. B., Ghobadi, A., Oluwole, O. O., Reagan, P. M., Lekakis, L. J., Lin, Y., et al. (2020) · Blood Advances

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 489

Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

Jain, M. D., Zhao, H., Wang, X., Atkins, R., Menges, M., Reid, K., Spitler, K., Faramand, R., Bachmeier, C., Dean, E. A., et al. (2021) · Blood

CAR-T cell therapy researchCancer Immunotherapy and Biomarkers

Cited by 297

High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma

Dean, E. A., Mhaskar, R. S., Lu, H., Mousa, M. S., Krivenko, G. S., Lazaryan, A., Bachmeier, C. A., Chavez, J. C., Nishihori, T., Davila, M. L., et al. (2020) · Blood Advances

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 256

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

Stein-Thoeringer, C. K., Saini, N. Y., Zamir, E., Blumenberg, V., Schubert, M.-L., Mor, U., Fante, M. A., Schmidt, S., Hayase, E., Hayase, T., et al. (2023) · Nature Medicine

CAR-T cell therapy researchGut microbiota and health

Cited by 255

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

Plaks, V., Rossi, J. M., Chou, J., Wang, L., Poddar, S., Han, G., Wang, Z., Kuang, S.-Q., Chu, F., Davis, R. E., et al. (2021) · Blood

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 199

Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma

Jain, M. D., Ziccheddu, B., Coughlin, C. A., Faramand, R., Griswold, A. J., Reid, K. M., Menges, M., Zhang, Y., Cen, L., Wang, X., et al. (2022) · Blood

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 91

A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Siddiqi, T., Jacobson, C. A., Westin, J. R., Chavez, J. C., Ghobadi, A., Herrera, A. F., LaCasce, A. S., et al. (2016) · Blood

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 27

Quality of life in caregivers of patients receiving chimeric antigen receptor T‐cell therapy

Barata, A., Hoogland, A. I., Hyland, K. A., Otto, A. K., Kommalapati, A., Jayani, R. V., Irizarry‐Arroyo, N., Collier, A., Rodriguez, Y., Welniak, T. L., et al. (2021) · Psycho-Oncology

Nursing care and researchCancer survivorship and care

Cited by 23

Psychosocial characteristics of patients undergoing cellular immunotherapies and their caregivers across time

Kirtane, K., Reblin, M., Oswald, L. B., Irizarry-Arroyo, N., McCormick, R., Locke, F. L., & Ketcher, D. (2023) · Leukemia & Lymphoma

Cancer survivorship and careCAR-T cell therapy research

Cited by 6